WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very Low Risk0–0
- Low Risk1–1
- Intermediate Risk2–2
- High Risk3–4
The WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome calculator is designed for bedside assessing prognosis of patients with myelodysplastic syndrome (MDS) based on WHO morphological classification, cytogenetics, and transfusion requirement in clinical practice. The resulting score directly guides clinician decision-making regarding initiating targeted.
Clinical Guidelines & Evidence
Assesses prognosis of patients with myelodysplastic syndrome (MDS) based on WHO morphological classification, cytogenetics, and transfusion requirement. The WPSS provides dynamic prognostic assessment throughout disease course and stratifies patients into five risk groups.
Clinical Indication
The WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome is indicated for bedside clinical practice to support Assesses prognosis of patients with myelodysplastic syndrome (MDS) based on WHO morphological classification, cytogenetics, and transfusion requirement. The WPSS provides dynamic prognostic assessment throughout disease course and stratifies patients into five risk groups.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
WPSS Score = WHO Category Score + Karyotype Score + Transfusion Requirement Score
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| who_category | string | Yes | WHO morphological classification of myelodysplastic syndrome(categorical) |
| karyotype | string | Yes | Cytogenetic risk category based on karyotype analysis(categorical) |
| transfusion_requirement | string | Yes | Regular red blood cell transfusion requirement(categorical) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Very Low Risk | Excellent prognosis |
| 1–1 | Low Risk | Good prognosis |
| 2–2 | Intermediate Risk | Moderate prognosis |
| 3–4 | High Risk | Poor prognosis |
| 5–6 | Very High Risk | Very poor prognosis |
Evidence-Based References (EBM)
- Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510. doi: 10.1200/JCO.2006.08.5696DOI: 10.1200/JCO.2006.08.5696
- Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433-1440. doi: 10.3324/haematol.2011.044602DOI: 10.3324/haematol.2011.044602
- Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). Leukemia. 2015;29(7):1502-1513. doi: 10.1038/leu.2015.55DOI: 10.1038/leu.2015.55